NEXGEL, INC. (NXGL) Form 8-K — Nov 18, 2026
NexGel's Board elected Aviv Argaman, a full-time professional investor and founder of Asymmetry Point Capital, as an independent director effective November 12, 2026, and appointed him to a newly formed special committee on November 18, 2026. The special committee — chaired by Steve Ciardiello with Jerome Zeldis and Argaman — will evaluate and negotiate the proposed business combination with Fountainhead LifeSciences and its affiliates, including Sequence LifeScience and NVISION Biomedical Technologies. No definitive merger agreement has been signed yet.
Key figures
- Note interest rate
- 10%
- Reverse split ratio
- 1-for-20 (effective October 12, 2026)
- Existing warrant shares
- 41667
- Conversion price per share
- 5.5
- Reduced warrant exercise price
- 13
- Original warrant exercise price
- 16
- Asymmetry point conversion shares
- 363636
- Asymmetry point note purchases usd
- 2000000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.